Skip to content
Menu

Barclays Maintains Overweight on Medline, Raises Price Target to $45

Benzinga Newsdesk 6 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Barclays analyst Glen Santangelo maintains Medline (NASDAQ:MDLN) with a Overweight and raises the price target from $43 to $45.

Barclays analyst Glen Santangelo maintains Medline (NASDAQ:MDLN) with a Overweight and raises the price target from $43 to $45.

Read at benzinga.com